Peptide injection-site reactions: redness, lumps and when it's an infection
Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board
- Mild redness, itching, soreness or a bruise at the injection site is common, even with approved peptide medicines.
- A soft lump in a spot used over and over is often lipohypertrophy, caused mainly by not rotating sites and by reusing needles.
- Spreading redness, warmth, pus or fever can mean infection. Slow infections from contaminated vials can appear weeks after the injection.
- Products made for research are not made or tested as sterile medicines for people, which adds infection risk no technique can fully remove.
What is normal
Any injection under the skin can cause a small local reaction. Approved peptide medicines document this in their labels. The label for EGRIFTA WR (tesamorelin) reports injection-site reactions, including redness, itching, pain, irritation and bruising, in 25% of treated patients against 14% on placebo during the first 26 weeks of trials, and advises rotating sites around the abdomen to reduce them (drug label, trial data) 1. The SKYTROFA (lonapegsomatropin) label tells users to rotate between and within regions to reduce the risk of lipoatrophy, a loss of fat under the skin (drug label) 2.
So a small red patch, a little itching or tenderness, or a bruise is common. Even placebo injections caused reactions in one in seven people in those trials 1.
| What you see | Usually means | What to do |
|---|---|---|
| Small red, itchy or sore patch | A common, local reaction to the injection | Rotate sites; watch it |
| Bruise | Listed among injection-site reactions on approved labels | Rotate sites; watch it |
| Soft, rubbery thickening where you always inject | Lipohypertrophy from repeated use of one spot | Stop using that area; rotate |
| Spreading redness, warmth, increasing pain, swelling, pus or fever | Possible infection | See a clinician promptly; urgently if feverish or spreading fast |
| A firm lump or a sore that keeps coming back or will not heal over weeks | Possible slow infection (such as nontuberculous mycobacteria) or a change in the fat under the skin | See a clinician and say what was injected |
Lumps from injecting the same spot
Repeated injections into one area can change the fat under the skin. The best-studied example is lipohypertrophy in people who inject insulin, a thickened, rubbery swelling at overused sites. A 2021 meta-analysis of 45 studies and 26,865 people found it in about 42% of insulin users (meta-analysis) 3. A 2025 meta-analysis of risk factors (two of its authors worked for a needle maker) found the strongest contributor was incorrect site rotation (odds ratio 8.85), followed by needle reuse (3.20) and more than five years of injections (meta-analysis) 4. A 2026 international consensus adds that it can make absorption unpredictable and push insulin needs up by as much as a quarter (expert consensus) 5.
Insulin is a peptide hormone, but these numbers come from insulin users, not from people injecting research peptides, so they show the mechanism rather than the rate for any particular product. The lesson transfers: rotate sites, do not keep injecting into a lump, and do not reuse needles.
When it is an infection
An injection can also carry an infection into the skin. See a clinician promptly for redness that spreads rather than fades, warmth, swelling, increasing pain, pus, red streaks, or fever and feeling unwell, and urgently if the redness spreads quickly or there is fever. Do not try to drain a lump yourself.
A second kind of infection is slower and easier to miss. Nontuberculous mycobacteria are environmental organisms that can enter the skin through an injection or procedure; a 2013 review lists skin and soft-tissue infection among their common forms outside the lungs and notes outbreaks caused by contaminated injected solutions or medications and poorly disinfected equipment (review) 6. Unlike tuberculosis, they are not known to pass from person to person, and only about one in ten of their infections occurs outside the lungs, which is one reason clinicians may not think of them at first 6. The review advises a high index of suspicion when someone presents with a subacute or chronic infection 6, and in the Spanish outbreak below patients were treated with clarithromycin, in some cases with amikacin, chosen by susceptibility testing 7, which is why it matters to tell a clinician exactly what was injected and where it came from.
What the outbreaks teach
Documented outbreaks show how ordinary shortcuts cause these infections. At a rural clinic in China in 2006, 35 people developed buttock abscesses after intramuscular injections; every case had received drugs mixed with saline from 100 mL multiple-dose bottles, investigators found a needle left in the bottles' rubber stoppers and reused, and Mycobacterium abscessus grew from abscesses and from the clinic's water supply. The investigators noted that 14% of the village's registered residents had received intramuscular drugs over three months, often for minor illnesses, a reminder of how many people one contaminated bottle can reach (outbreak investigation) 8. In France, severe infections after mesotherapy, injections of mixtures into the skin for cosmetic purposes, were linked to a multiple-injection device cleaned with tap water (outbreak investigation) 9. In Spain in 2009, 17 of 77 patients of an aesthetic clinic, healthy women, developed M. abscessus abscesses after mesotherapy with homeopathic products from multi-dose vials; the clinic's equipment and procedures were judged correct, and investigators thought contamination at the factory the most likely cause, without laboratory confirmation (outbreak investigation) 7.
The common thread is contamination of something used more than once, or of the product itself: a bottle, a needle, a device, a multi-dose vial. Home injection of peptides from multi-use vials, reconstituted with water and drawn repeatedly, has the same structure.
Vials, water and what sterile means
CDC's injection-safety guidance describes a multi-dose vial as one approved for repeated use that typically contains an antimicrobial preservative to help limit the growth of bacteria; the preservative has no effect on viruses and does not give complete protection against bacterial contamination, a point its training material repeats 10 11. CDC advises that such an opened or needle-punctured multi-dose vial from a manufacturer be dated and discarded within 28 days unless the manufacturer gives a different date, never beyond the original expiry, and that any vial whose sterility is in question be discarded 10. A vial mixed at home is not one of those: the bacteriostatic water label says a drug dissolved in it should be used promptly and not stored unless the drug's maker directs otherwise 12. Our bacteriostatic water guide explains why the choice of diluent matters.
The bigger issue for research peptides is that they are not made as sterile medicines for people. US manufacturing rules require each batch of a drug product that purports to be sterile or pyrogen-free to be tested for it 13; a powder labelled for research use carries no such assurance, so careful technique at home cannot fix contamination that came in the vial. Our guide to what research use only means covers that gap.
Where approved peptides are injected
The labels of approved injectable peptides are a practical guide to sites. Wegovy and Zepbound are injected under the skin of the abdomen, thigh or upper arm, with Zepbound's label specifying the back of the upper arm when another person gives the injection 14. EGRIFTA WR is injected into the abdomen, rotating sites around it 1. SKYTROFA, a weekly growth hormone, goes into the abdomen, buttock or thigh, rotating between and within those regions 2. Every one of these labels builds rotation into the instructions.
Keeping a note of the last site used makes rotation easier to follow. In insulin users, incorrect rotation was the factor most strongly linked with fatty lumps 4.
Basic precautions
- Use a new sterile needle and syringe for every injection, and never put a used needle back into a vial; the saline-bottle outbreak above began with a reused needle left in a stopper 8.
- Do not leave a needle in a vial's stopper for repeated use 10.
- Rotate injection sites within and between areas, and avoid lumps, bruises and broken skin 4 2.
- Date opened vials and discard them as their makers direct; a manufacturer's multi-dose vial with no date given goes within 28 days 10, and a vial you mix yourself should be used promptly, as the bacteriostatic water label says 12. Discard anything cloudy, discoloured or doubtful 10.
- Do not share needles, syringes or pens with anyone; CDC's rule for clinics is never to reuse a needle or syringe on more than one person 10.
Lumps that do not go away
Some lumps are neither a simple reaction nor an obvious infection: a firm nodule that persists for weeks or months. Possible causes include a slow mycobacterial infection 6 or changes in the fat under the skin such as lipohypertrophy or lipoatrophy 3 2. These are hard to tell apart without an examination, and sometimes a culture or biopsy. A persistent lump after injecting an unapproved product is a reason to see a clinician, not a reason to keep injecting nearby.
When to see a clinician
Seek care promptly for redness that spreads or keeps growing after the first day, warmth and swelling with increasing pain, pus or a lump that feels fluid-filled, red streaks, fever, chills or feeling unwell, or a sore that will not heal. Seek care for any lump that persists beyond a couple of weeks or keeps coming back. Seek emergency care for signs of a severe allergic reaction, such as swelling of the face or throat, trouble breathing or a widespread rash, after any injection.
Bring the product with you, or its name, batch and where it was bought, along with the date you first noticed the change and the dates of recent injections. Slow mycobacterial infections are easy to miss without that history 6.
The bottom line
Mild redness or a bruise is common after injections of approved peptides, and poor site rotation is the factor most strongly linked with lumps from repeated use. Infections are less common but more serious, and the slow ones from contaminated vials or equipment can surface weeks later and resist ordinary antibiotics. With research products that were never made as sterile medicines, the safest technique still cannot guarantee a sterile injection, so any worsening, spreading or persistent change deserves a clinician's look.
Frequently asked questions
Is a red bump after a peptide injection normal?
A small red, itchy or tender patch that fades within a day or two is common. Approved injectable peptides report such reactions, and even placebo injections cause some.
Why do I have a lump where I inject?
Often from injecting the same spot repeatedly, which can thicken the fat under the skin. In insulin users, poor site rotation and needle reuse are the strongest risk factors. A lump that is hot, painful or growing needs a clinician.
How do I know if my injection site is infected?
Spreading redness, warmth, swelling, increasing pain, pus, red streaks or fever suggest infection and need prompt care. Slow infections can appear as firm lumps weeks later.
Can contaminated vials cause infections?
Yes. Outbreaks of slow mycobacterial infections have been traced to contaminated multi-dose saline bottles and poorly cleaned injection equipment.
Should I keep injecting if a site is sore?
Rotate to a different area and watch the sore site. Stop and see a clinician if it worsens, spreads or persists.
Related on Grey Peptides
Sources
- Theratechnologies. EGRIFTA WR (tesamorelin) US prescribing information, sections 2.1 and 5.6 (Injection Site Reactions). DailyMed version 2, effective July 29, 2026; read October 1, 2026. DailyMed
- Ascendis Pharma. SKYTROFA (lonapegsomatropin-tcgd) US prescribing information, section 2 (Dosage and Administration: rotation of injection sites). DailyMed version 14, effective October 21, 2026; read October 27, 2026 (section 2 unchanged since it was first read on October 1, 2026). DailyMed
- Wang, K., et al. (2021). A meta-analysis and meta-regression on the prevalence of lipohypertrophy in diabetic patients on insulin therapy. Therapie, 76(6), 617-628. PMID: 33958198
- Mader, J. K., et al. (2026). Risk factors for Lipohypertrophy in People With Insulin-Treated Diabetes: A Systematic Meta-Analysis. J Diabetes Sci Technol, 20(4), 1342-1352. PMID: 40109173
- Guo, L., et al. (2026). Consensus Recommendations on Lipohypertrophy: Insights From an International Panel of Experts. Diabetes Res Clin Pract, 239, 113401. PMID: 42398590
- Kasperbauer, S., et al. (2013). Management of extrapulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med, 34(1), 143-50. PMID: 23460014
- Galmés-Truyols, A., et al. (2011). An outbreak of cutaneous infection due to Mycobacterium abscessus associated to mesotherapy. Enferm Infecc Microbiol Clin, 29(7), 510-4. PMID: 21684045
- Yuan, J., et al. (2009). Mycobacterium abscessus post-injection abscesses from extrinsic contamination of multiple-dose bottles of normal saline in a rural clinic. Int J Infect Dis, 13(5), 537-42. PMID: 19269204
- Carbonne, A., et al. (2009). Outbreak of nontuberculous mycobacterial subcutaneous infections related to multiple mesotherapy injections. J Clin Microbiol, 47(6), 1961-4. PMID: 19386853
- Centers for Disease Control and Prevention. Preventing Unsafe Injection Practices (Injection Safety: clinical safety). Last reviewed March 26, 2024; read October 2 and October 27, 2026 (multi-dose vial definition and preservative, 'does not have an effect on viruses', the dating and discard rule for a manufacturer's opened multi-dose vial, needle left in a septum, needle and syringe reuse). CDC
- Centers for Disease Control and Prevention. Safe Injection Practices, Module 6 (dental infection control training script). Read October 2, 2026. CDC
- Hospira, Inc. Bacteriostatic Water for Injection, USP, prescribing information: when diluting or dissolving drugs, mix thoroughly and use promptly; do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute. DailyMed set 87d6e9dc, version 20, effective May 22, 2026; read October 27, 2026. DailyMed
- 21 CFR 211.167(a), Current Good Manufacturing Practice for Finished Pharmaceuticals: for each batch of drug product purporting to be sterile and/or pyrogen-free, appropriate laboratory testing to determine conformance. Read October 27, 2026. eCFR
- Novo Nordisk. WEGOVY (semaglutide) and Eli Lilly. ZEPBOUND (tirzepatide) US prescribing information, Dosage and Administration (injection sites). DailyMed versions 19 (effective June 18, 2026) and 40 (effective August 28, 2026); read October 1, 2026. DailyMed
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead